Latest Acute Kidney Injury (AKI) News
The Food and Drug Administration (FDA) announced it is strengthening the current warning about the risk of acute kidney injury for drug products containing canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).
Male gender, diabetes, and renal function decline at 90 days implicated as risk factors; patients rarely progress to end-stage renal disease.
Japanese study demonstrates a 2-fold increased risk of death from any cause.
High FiO2 and norepinephrine in AKI patients increases their risk of death within 24 hours of being placed on continuous renal replacement therapy.
Study demonstrates improved 90-day survival and greater likelihood of recovering renal function.
Patients were 40% less likely to die in 2011 compared with 2001, study finds.
Mortality no different for early versus delayed strategy for patients with severe acute kidney injury.
Nearly 6% of patients who underwent partial or radical nephrectomy between 1998 and 2010 developed AKI.
Poor long-term outcomes found even in patients with community-acquired AKI but not hospitalized.
Statins don't prevent complications and may cause acute kidney injury, researchers report.
Treatment linked to improved long-term survival, regardless of underlying kidney function.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
The addition of aliskiren to enalapril led to more adverse events in patients with chronic heart failure without an increase in benefit.
Study finds no significant difference in the rates of all-cause mortality, major cardiac events, and hospital admission with hyperkalemia or AKI.
10% of the population worldwide is impacted by some form of kidney damage.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)